Benzoic acid derivative MDM2 inhibitor for the treatment of cancer
    4.
    发明授权
    Benzoic acid derivative MDM2 inhibitor for the treatment of cancer 有权
    苯甲酸衍生物MDM2抑制剂治疗癌症

    公开(公告)号:US08952036B2

    公开(公告)日:2015-02-10

    申请号:US14192553

    申请日:2014-02-27

    申请人: Amgen Inc.

    发明人: Yosup Rew

    IPC分类号: A61K31/45 C07D211/76

    CPC分类号: A61K31/45 C07D211/76

    摘要: The present invention provides a MDM2 inhibitor compound, or a pharmaceutically acceptable salt thereof, which compound is useful as a therapeutic agent, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contains the MDM2 inhibitor.

    摘要翻译: 本发明提供一种MDM2抑制剂化合物或其药学上可接受的盐,该化合物可用作治疗剂,特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。

    AMORPHOUS AND CRYSTALLINE FORMS OF MCL-1 ANTAGONISTS

    公开(公告)号:US20240140966A1

    公开(公告)日:2024-05-02

    申请号:US18296211

    申请日:2023-04-05

    申请人: AMGEN INC.

    IPC分类号: C07D513/10

    CPC分类号: C07D513/10

    摘要: Disclosed herein are crystalline and amorphous forms of (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2H, 15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6,019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (AMG 176):




    and salts and hydrates thereof. Also disclosed are methods of making the crystalline and amorphous forms, and methods of treating diseases and disorders with the crystalline and amorphous forms.